FHIR © HL7.org  |  Server Home  |  FHIR Server FHIR Server 3.7.22-SNAPSHOT  |  FHIR Version n/a  User: [n/a]

771591006: Tildrakizumab (substance)

Status: current, Not sufficiently defined by necessary conditions definition status (core metadata concept). Date: 31-Jan 2019. Module: SNOMED CT core

Descriptions:

Id Description Lang Type Status Case? Module
3706923013 Tildrakizumab (substance) en Fully specified name Active Entire term case insensitive (core metadata concept) SNOMED CT core
3706924019 Tildrakizumab en Synonym (core metadata concept) Active Entire term case insensitive (core metadata concept) SNOMED CT core
363871000195111 tildrakizumab it Synonym (core metadata concept) Active Entire term case insensitive (core metadata concept) SNOMED CT Switzerland NRC maintained Module
1137381000241113 tildrakizumab fr Synonym (core metadata concept) Active Entire term case insensitive (core metadata concept) SNOMED CT Switzerland NRC maintained Module
3334881001000116 Tildrakizumab de Synonym (core metadata concept) Active Entire term case sensitive (core metadata concept) SNOMED CT Switzerland NRC maintained Module

0 descendants.

Expanded Value Set

Outbound Relationships Type Target Active Characteristic Refinability Group Values
Tildrakizumab (substance) Is a Monoclonal antibody false Inferred relationship Some
Tildrakizumab (substance) Is a Substance with interleukin 23 receptor antagonist mechanism of action (substance) true Inferred relationship Some
Tildrakizumab (substance) This attribute specifies the behavior that a substance will exhibit or participate in, given the appropriate context. Interleukin 23 receptor antagonist (disposition) true Inferred relationship Some
Tildrakizumab (substance) Is a Immunosuppressant (substance) true Inferred relationship Some
Tildrakizumab (substance) Is a Monoclonal immunoglobulin G (substance) true Inferred relationship Some
Inbound Relationships Type Active Source Characteristic Refinability Group
Product containing tildrakizumab in parenteral dose form (medicinal product form) The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. True Tildrakizumab (substance) Inferred relationship Some 1
Product containing tildrakizumab (medicinal product) The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. True Tildrakizumab (substance) Inferred relationship Some 1
Product containing only tildrakizumab (medicinal product) The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. True Tildrakizumab (substance) Inferred relationship Some 1
Tildrakizumab only product in parenteral dose form The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. True Tildrakizumab (substance) Inferred relationship Some 1
Tildrakizumab 100 mg/mL solution for injection The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). True Tildrakizumab (substance) Inferred relationship Some 1
Tildrakizumab 100 mg/mL solution for injection This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. True Tildrakizumab (substance) Inferred relationship Some 1

Reference Sets

GB English

US English

Back to Start